GKOS: Recent Approvals And Facility Expansion Will Drive Stock Higher

Analysts have increased their price target for Glaukos to $120.50 from $119.85, citing continued strong performance, an improved growth outlook, and underappreciated product drivers that are fueling optimism for the company's future trajectory.

Analyst Commentary

Recent Street research highlights a predominance of positive sentiment toward Glaukos, with several firms raising price targets and pointing to key growth drivers. While the majority of commentary is upbeat, some analysts also note factors that could temper short-term expectations.

• Bullish analysts are raising price targets in response to Glaukos' consistent "beat and raise" quarterly performance, suggesting strong execution and upward revisions to growth outlooks.
• Optimism persists around the company's pipeline, particularly iDose. This product is seen as a catalyst for multi-year revenue growth and a key value driver for the stock.
• Epioxa is highlighted as a significant, underappreciated growth opportunity. There are expectations that its broader label and benefits could justify substantial pricing power relative to predecessor products.
• The recent pullback in Glaukos shares is viewed by some as an opportunity to buy. Analysts forecast that easing reimbursement bottlenecks and expanding physician fees could further accelerate adoption into 2026.

• Some caution remains amid recent target reductions. Concerns have arisen that prior momentum may slow as the market digests valuation gains from earlier in the year.
• Uncertainties around the pace and breadth of iDose reimbursement, despite progress, continue to be noted as a factor that could impact revenue ramp timing.
• Analysts highlight that the stock's recent positive positioning could reverse if execution slows or if new product launches take longer than expected to gain traction.

What's in the News

• Glaukos raised its revenue guidance for 2025 and now projects net sales of $490 million to $495 million, up from its previous expectation of $480 million to $486 million (Key Developments).
• The company issued preliminary revenue guidance for 2026 and forecasts net sales between $600 million and $620 million based on the latest foreign currency rates (Key Developments).
• The U.S. Food and Drug Administration (FDA) approved Glaukos' Epioxa HD/Epioxa, advanced treatments for keratoconus, following successful Phase 3 clinical trials involving over 400 patients (Key Developments).
• Glaukos broke ground on a new research, development, and manufacturing facility in Huntsville, Alabama. The project is expected to create over 150 full-time jobs and involve more than $80 million in planned capital expenditures (Key Developments).

Valuation Changes

• The consensus analyst price target has risen slightly to $120.50, up from $119.85.
• The discount rate increased modestly from 7.48% to 7.72%.
• The revenue growth projection edged higher, moving from 26.46% to 26.65%.
• The net profit margin estimate fell from 9.57% to 8.93%.
• The future P/E ratio increased slightly, rising from 104.72x to 106.07x.